<b>Gapping up <br/>In reaction to strong earnings/guidance: </b>CAMP +11.2%, MU +4%, ZHNE +1.5%<br/><br/><b>M&A news:</b> PMCS +6.8% (following late move higher on report of potential sale), STO +2.6% (acquires First Oil's 24% equity share in the UK licence for the Alfa Sentral field for $15 mln)<br/><br/><b>Select financial related names showing strength:</b> CS +2.1%, DB +2.1%, RBS +2%, HSBC +2%, BCS +1.8%, ING +0.8%<br/><br/><b>Select notable European stocks trading higher: </b>STM +1.9%, TS +1.8%, SAP +1.7%, ALV +1.7%, NOK +1.6%, ASML +1.6%, CCL +1.4%, SHPG +1.3%, DEO +1.1%, ARMH +1%<br/><b><br/>Select oil/gas related names showing strength:</b> BP +3.4%, TOT +3.4%, RDS.A +3.3%, AEG +2.5%, PBR +2.4%, SDRL +2%, HAL +1.9%, RIG +1.8%, VLO +1.4%<br/><br/><b>Other news:</b> BEBE +12.6% (announces a workforce reorganization; authorizes a$5 million share repurchase program), WYNN +7.9% (reports that Macau casinos may soon receive economic support from China), XNPT +7.8% (seeks to focus on and maximize the value of its commercial product Horizant; will discontinue development of XP23829 on its own and seek a partner ), CHRS +6.2% (Coherus BioSciences reported the results from its pharmacokinetic and pharmacodynamic clinical study of CHS-1701, a pegfilgrastim (Neulasta) biosimilar candidate. This study met its primary PD endpoints ), LVS +5.1% (reports that Macau casinos may soon receive economic support from China), MGM +4.2% (reports that Macau casinos may soon receive economic support from China), JWN +3.6% (Nordstrom announces closing of its credit card transaction; $1.8 billion net proceeds to be returned to shareholders through dividend and share repurchase; board authorizes special cash dividend of $4.85 per share), BCOR +3% (co its InfoSpace subsidiary enter into a Mutual Termination Agreement with Yahoo! (YHOO)), NEWR +2.3% (co's Chief Revenue Officer Hilarie Koplow-McAdams promoted to the role of President), RGR +2.2% (FBI released NICS background checks data; Sept Total NICS Background Checks were 1795102 vs 1745410 prior month and 1456032 in prior year), SUNE +1.9% (cont strength), S +1.7% (plans to eliminate nearly $2.5 bln in costs, according to WSJ), SRPT +1.2% (announced a four year collaborative research agreement, to establish the Sarepta Translational Laboratory with Murdoch University in Western Australia)<br/><br/><b>Analyst comments:</b> SUM +3.3% (upgraded to Buy from Neutral at Goldman), FINL +1.2% (upgraded to Neutral from Sell at Goldman), AAPL +0.7% (initiated with a Buy at Drexel Hamilton; tgt $200), GOOG +0.6% (upgraded to Outperform from Perform at Oppenheimer; $700 tgt), FB +0.5% (resumed with a Outperform at Wedbush; tgt $115) <br/><b><br/>Gapping down<br/>In reaction to disappointing earnings/guidance:</b> PRGS -14.2%, BOOM -2.9%<br/><br/><b>Select metals/mining stocks trading lower: </b>AU -2.3%, GFI -1.6%, VALE -0.9%, AEM -0.7%, SLV -0.7%, GLD -0.6%, GDX -0.5%<br/><br/><br/><b>Other news: </b>GMCR -2.8% (President of U.S. Sales and Marketing John Whoriskey's previously announced retirement became effective September 30 ), O -2.3% (prices 10,000,000 shares of common stock at $46.88 per share), CIVI -1.6% (prices its downsized offering of 2 mln shares on behalf of selling shareholders at $21.50/share), REGN -1.5% (announced a collaboration with Mitsubishi Tanabe Pharma Corporation; providing MTPC with exclusive development and commercial rights to fasinumab ), CPST -1.3% (cont weakness)<br/><br/><b>Analyst comments:</b> VRX -2.5% (downgraded to Equal Weight from Overweight at Morgan Stanley), REGN -1.5% (downgraded to Equal-Weight from Overweight at Morgan Stanley), GILD -0.5% (downgraded to Equal Weight from Overweight at Morgan Stanley)<br/>Briefing.com